ATAGI सलाह mRNA COVID-19 वैक्सीन खुराक अंतराल और COVID-19 टीकाकरण पोस्ट संक्रमण पर
ATAGI ने mRNA COVID-19 वैक्सीन खुराक अंतराल और COVID-19 टीकाकरण पोस्ट संक्रमण पर अद्यतन सलाह प्रदान की है।
अब यह सिफारिश की जाती है कि mRNA COVID-19 टीकों की प्राथमिक खुराक के बीच खुराक अंतराल को 8 सप्ताह तक बढ़ाया जाना चाहिए, साथ ही विस्तारित खुराक अंतराल को टीकाकरण के लिए प्रभावशीलता और प्रतिरक्षा प्रतिक्रिया में सुधार के साथ-साथ संभावित रूप से मायोकार्डिटिस के जोखिम को कम करने के लिए दिखाया गया है। पेरिकार्डिटिस।
ATAGI ने यह भी सिफारिश की है कि COVID-19 टीकाकरण को COVID-19 संक्रमण के बाद 3 महीने के लिए टाल दिया जाए ताकि सुरक्षा का अनुकूलन किया जा सके।
अद्यतन अनुशंसाओं को पूर्ण रूप से पढ़ने के लिए, कृपया नीचे दिए गए लिंक पर क्लिक करें।
ATAGI सलाह mRNA COVID-19 वैक्सीन खुराक अंतराल और COVID-19 टीकाकरण पोस्ट संक्रमण पर
COVID-19 वैक्सीन प्रशासन त्रुटियों पर ATAGI नैदानिक मार्गदर्शन
ATAGI has provided the below guidance for clinicians outlining the appropriate management of common COVID-19 vaccine administration errors. It includes scenarios where the vaccine is administered in the following circumstances:
- Via the incorrect site/route
- At a higher/lower dose
- Following incorrect storage and handling
- In an unapproved age group
- Mixed vaccine schedules
- With incorrect intervals
It is important to note that in Victoria, any vaccine administration error should be reported to सैफविक. Following the identification of a vaccine error, open disclosure with the vaccine recipient is important and addressing the cause of the error will prevent errors from occurring again in the future.
To read the full guideline, follow the link below:
COVID-19 वैक्सीन प्रशासन त्रुटियों पर ATAGI नैदानिक मार्गदर्शन
ATAGI update following weekly COVID-19 meeting – 16 February 2022
ATAGI held their weekly meeting on Wednesday 16 February to discuss the latest developments and recommendations relating to COVID-19 immunisations.
The meeting addressed the use of Moderna’s COVID-19 vaccine in children aged 6 to 11 years, as well as, the use of Novavax’s COVID-19 vaccine as a booster and recommendations regarding the vaccine dose interval for children.
To read the full update, follow the link below:
ATAGI update following weekly COVID-19 meeting – 16 February 2022
Omicron variant: will the COVID-19 Pfizer, Moderna, AstraZeneca vaccines protect you?
Scientists around the world are looking at whether protective antibodies in the current COVID-19 vaccines are “sufficiently high” to cover the new Omicron strain. Additionally, the WHO and governments are assessing the severity of the new variant.
Vaccine makers, including Pfizer and Moderna have been working on “next-generation” mRNA vaccines that would be able to target particular variants circulating. Current data suggests that the COVID-19 vaccines used in Australia will protect against severe disease.
To read the full article, please click on the link below:
Omicron variant: will the COVID-19 Pfizer, Moderna, AstraZeneca vaccines protect you?